Startups · 10h ago
Colossal Biosciences eyes $20B–$30B valuation in new funding round
Colossal Biosciences, a startup focused on de-extinction technology, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion. This would double or triple its previous valuation. The company uses genetic engineering to revive extinct species like the woolly mammoth.
Meridian48 take
The massive valuation jump reflects investor appetite for speculative biotech, but de-extinction remains unproven at scale and years from commercial application.
Read the full reporting
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation →
TechCrunch
de-extinctionbiotech-valuation